Eli Lilly's GLP-1 Impact on ResMed Is Overblown: Barron's
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
Top Gap Ups and Downs on Friday: WFC, DKS, BK and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
European stock markets rose as US inflation slowed, boosting market sentiment.
European stock markets rose on Friday, achieving their best weekly performance in two months due to slowing US inflation and rising expectations of a September rate cut by the Federal Reserve, which boosted investor sentiment. The Stoxx Europe 600 index rose 0.9% to a high not seen since early June, mirroring gains in the US and boosting risk assets on expectations of a possible rate cut there. Almost all sectors rose, led by consumer stocks, technology firms and retailers. Novo Nordisk, ASML Holding, Siemens and LVMH had the biggest positive impact on the index. Luxury goods companies, which had seen their expected profit declines outpace the broader European market, rebounded on Friday. Uncertainty around the French and British elections.
PFE or NVO: Which Is the Better Value Stock Right Now?
These Are the Weight Loss Drug Stocks With the Most Upside - SA Sentiment Survey
Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
On Friday, the European Medicines Agency (EMA) warned patients using weight-loss drugs, such as Novo Nordisk A/S's (NYSE:NVO) Wegovy, to inform their doctors before general anesthesia or deep
Pharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development
The EU accuses Eli Lilly and Co (LLY.US) and Novo Nordisk A/S (NVO.US) of having risks of post-anesthetic pulmonary inhalation in weight-loss and blood-sugar-lowering drugs.
European health departments warn that there may be a risk of anesthesia complications for patients who are taking glucose-lowering and weight-loss medications before surgery.
Novo Nordisk's Ozempic Reduces Dementia and Cognitive Risks, Oxford Study Says
Novo Nordisk's (NVO) Ozempic may reduce the risk of dementia and other neurological issues compared to older antidiabetic medications like sitagliptin and glipizide, according to a study by the
A study by the University of Oxford showed that Ozempic, a weight loss drug from Novo Nordisk A/S (NVO.US), is associated with reducing the incidence of dementia.
A study by Novo Nordisk's weight loss drug Ozempic (Semaglutide) at Oxford University found that it is associated with reducing the incidence of dementia and a range of other mental illnesses.
Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds
Novo Nordisk A/S. (NYSE:NVO) has found that its "miracle" weight loss drug used for diabetes, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues.
This Weight Loss Stock Is the Best Alternative to Eli Lilly, Novo - SA Sentiment
Top Gap Ups and Downs on Thursday: IBKR, DAL, VOD and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
PepsiCo CEO: GLP-1 Drugs Are 'Not Impacting Us'
Novo Nordisk (NYSE:NVO) Slides After FDA Turns Down Insulin Drug
Eli Lilly, Novo Nordisk Shares Dip as Pfizer Ramps Up Diabetes Drug Competition
Shares of $Eli Lilly and Co(LLY.US)$ and $Novo-Nordisk A/S(NVO.US)$ finished lower on Thursday, perhaps influenced by competitive developments and regulatory updates in the pharmaceutical sector.
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
Senator Bernie Sanders expressed confidence that Novo Nordisk A/S (NYSE:NVO) can be persuaded to reduce the U.S. prices of its popular weight-loss drugs, Ozempic and Wegovy, by publicly highlighting the disparity between domestic and international pricing.
Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading
European equities traded in the US as American depositary receipts were trending slightly higher late Thursday morning, rising 0.19% to 1,460.27 on the S&P Europe Select ADR Index.From continental